Drug intelligence / Profile preview

CPA

Development stage: Unknown
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

CPA is an abbreviation used in clinical contexts for multiple distinct pharmaceutical drugs. One prominent drug referred to as CPA is **Cyclophosphamide**, an alkylating agent used as a chemotherapy drug and an immunosuppressant. It is investigated for various cancers, including relapsed/refractory Diffuse Large B-cell Lymphoma, Stage IV Melanoma, platinum-resistant ovarian cancer, and non-small cell lung cancer, often in combination with immunotherapies or other agents. Another drug referred to as CPA is **Cyproterone Acetate**, which is an antiandrogen and progestin. It is used in conditions like Polycystic Ovarian Syndrome (often as part of Diane-35) and in gender-affirming hormone therapy for transgender women.

Other names: CyclophosphamideCyproterone Acetate

Targets

GR (Glucocorticoid receptor)PR (Progesterone receptor)AR (Adrenergic receptors)

Beyond the preview

Go deeper on CPA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CPA.

Explore the full profile